ArticleThe Indian journal of radiology & imaging2026
Balloon-Occluded Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma.
Article in The Indian journal of radiology & imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transarterial chemoembolization (TACE) is considered standard therapy for intermediate-stage hepatocellular carcinoma (HCC). However, conventional TACE (cTACE) and drug-eluting bead TACE (DEB-TACE) are limited by high recurrence rates. Recent studies have shown that balloon-occluded TACE (B-TACE) allows enhanced intratumoral drug deposition and may improve outcomes. This study aimed to evaluate the short-term outcome of B-TACE for HCC. Materials and Methods: This retrospective single-center study was conducted after obtaining approval from the institutional review board. Fifty patients with unresectable HCC were treated with B-TACE between October 2023 and September 2024. Tumor response was assessed using LI-RADS Treatment Response (LR-TR) and mRECIST (Modified Response Evaluation Criteria in Solid Tumors). Progression-free survival (PFS) was analyzed with Kaplan-Meier methods, and predictors of response were evaluated by logistic regression. Lipiodol deposition was classified into three types as a surrogate marker of drug distribution. Results: The overall response rate was 72.0%, with a complete response in 54.0% of patients. Subgroup analysis revealed that patients with Barcelona Clinic Liver Cancer (BCLC) stage A and B achieved a higher overall response rate of 77.3% (34/44), compared with 33.3% (2/6) in patients with BCLC stage C. At 1 year, 68.0% remained progression-free, with significantly higher PFS in those achieving early complete response/partial response compared with stable disease/progressive disease (83.3 vs. 28.6%, Conclusion: B-TACE demonstrated high efficacy and acceptable safety in HCC, with lipiodol deposition serving as a key predictor of outcome. These findings support B-TACE as a promising alternative to cTACE/DEB-TACE, particularly in intermediate-stage disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.